Anúncio
Anúncio
ALNY
Alnylam Pharmaceuticals, Inc.
397.68
USDPatrocinado
+0.43
+0.11%
31 de dez., 16:00 UTC -5
Encerrado
Pós-Mercado
397.69
0.00
0.00%
Relatórios de Lucros ALNY
Rácio de surpresa positiva
ALNY separação 21 de 39 últimas estimativas.
54%
Próximo Relatório
Data do Próximo Relatório
12 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.20B
/$1.24
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-4.19%
/-41.23%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+101.75%
/-290.77%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On 30 de out. de 2025, ALNY reported earnings of 2.11 USD per share (EPS) for Q3 25, beating the estimate of 0.76 USD, resulting in a 177.16% surprise. Revenue reached 1.25 bilhão, compared to an expected 997.35 milhão, with a 25.23% difference. The market reacted with a -6.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 28 analistas forecast an EPS of 1.24 USD, with revenue projected to reach 1.20 bilhão USD, implying an diminuir of -41.23% EPS, and diminuir of -4.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alnylam Pharmaceuticals, Inc. reported EPS of $2.11, beating estimates by 177.16%, and revenue of $1.25B, 25.23% above expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q3 2025 earnings?
The stock price moved down -6.65%, changed from $481.59 before the earnings release to $449.56 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for 12 de jan. de 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 28
analistas, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.24 and revenue of $1.20B for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio